Miguel Orri1, Craig H Lipset2, Bradly P Jacobs3, Anthony J Costello4, Steven R Cummings5. 1. Pfizer Ltd, Tadworth, United Kingdom. Electronic address: miguel@orri.co.uk. 2. Pfizer Inc, New York, NY, USA. 3. University of California-San Francisco, San Francisco, CA, USA; Mytrus, San Francisco, CA, USA. 4. University of California-San Francisco, San Francisco, CA, USA. 5. University of California-San Francisco, San Francisco, CA, USA; Mytrus, San Francisco, CA, USA; California Pacific Medical Center Research Institute, San Francisco, CA, USA.
Abstract
INTRODUCTION: Participatory patient-centered, web-based methods could streamline and improve the convenience of clinical trial participation. We used an entirely web-based approach to conduct a randomized, placebo-controlled, Phase 4 (REMOTE) trial under an Investigational New Drug (IND) application to evaluate tolterodine extended release (ER) 4 mg for overactive bladder. METHODS: The trial was designed to replicate previous clinic-based trials of tolterodine ER but was conducted via the web from one clinical site overseen by physicians. Participants were recruited via the web, screened for eligibility using web-based questionnaires, had laboratory testing in their community, and entered a run-in phase requiring bladder e-diaries. Informed consent was obtained using an interactive web-based method with physician countersignature. Study medication was shipped directly to participants. RESULTS: With a goal of 283 randomized participants, 5157 registered on the trial website. Of 456 who passed initial screening, identification verification, and signed consent, 237 passed additional medical screening and were countersigned by the investigator. After laboratory testing, 118 entered the placebo run-in; only 18 passed e-diary assessments and were randomized to treatment. At week 12, the mean change from the baseline in micturitions/24 hours (primary endpoint) was -2.4 for tolterodine ER versus -0.8 for placebo [treatment difference (95% CI): -1.6 (-3.9, 0.6)]. CONCLUSION: The REMOTE trial is the first entirely web-based trial conducted under an IND application. The efficacy observed was consistent with results from conventional trials. With simplification of multi-step screening and testing, web-based trials or their component parts should provide a participant-friendly approach to many clinical trials.
RCT Entities:
INTRODUCTION: Participatory patient-centered, web-based methods could streamline and improve the convenience of clinical trial participation. We used an entirely web-based approach to conduct a randomized, placebo-controlled, Phase 4 (REMOTE) trial under an Investigational New Drug (IND) application to evaluate tolterodine extended release (ER) 4 mg for overactive bladder. METHODS: The trial was designed to replicate previous clinic-based trials of tolterodine ER but was conducted via the web from one clinical site overseen by physicians. Participants were recruited via the web, screened for eligibility using web-based questionnaires, had laboratory testing in their community, and entered a run-in phase requiring bladder e-diaries. Informed consent was obtained using an interactive web-based method with physician countersignature. Study medication was shipped directly to participants. RESULTS: With a goal of 283 randomized participants, 5157 registered on the trial website. Of 456 who passed initial screening, identification verification, and signed consent, 237 passed additional medical screening and were countersigned by the investigator. After laboratory testing, 118 entered the placebo run-in; only 18 passed e-diary assessments and were randomized to treatment. At week 12, the mean change from the baseline in micturitions/24 hours (primary endpoint) was -2.4 for tolterodine ER versus -0.8 for placebo [treatment difference (95% CI): -1.6 (-3.9, 0.6)]. CONCLUSION: The REMOTE trial is the first entirely web-based trial conducted under an IND application. The efficacy observed was consistent with results from conventional trials. With simplification of multi-step screening and testing, web-based trials or their component parts should provide a participant-friendly approach to many clinical trials.
Authors: Ethan M Balk; Gaelen P Adam; Katherine Corsi; Amanda Mogul; Thomas A Trikalinos; Peter C Jeppson Journal: J Gen Intern Med Date: 2019-05-06 Impact factor: 5.128
Authors: Carmen Rosa; Aimee N C Campbell; Gloria M Miele; Meg Brunner; Erin L Winstanley Journal: Contemp Clin Trials Date: 2015-07-12 Impact factor: 2.226
Authors: Abhishek Pratap; Elias Chaibub Neto; Phil Snyder; Carl Stepnowsky; Noémie Elhadad; Daniel Grant; Matthew H Mohebbi; Sean Mooney; Christine Suver; John Wilbanks; Lara Mangravite; Patrick J Heagerty; Pat Areán; Larsson Omberg Journal: NPJ Digit Med Date: 2020-02-17
Authors: E Ray Dorsey; Meredith A Achey; Christopher A Beck; Denise B Beran; Kevin M Biglan; Cynthia M Boyd; Peter N Schmidt; Richard Simone; Allison W Willis; Nicholas B Galifianakis; Maya Katz; Caroline M Tanner; Kristen Dodenhoff; Nathan Ziman; Jason Aldred; Julie Carter; Joohi Jimenez-Shahed; Christine Hunter; Meredith Spindler; Zoltan Mari; John C Morgan; Dedi McLane; Patrick Hickey; Lisa Gauger; Irene Hegeman Richard; Michael T Bull; Nicte I Mejia; Grace Bwala; Martha Nance; Ludy Shih; Lauren Anderson; Carlos Singer; Cindy Zadikoff; Natalia Okon; Andrew Feigin; Jean Ayan; Christina Vaughan; Rajesh Pahwa; Jessica Cooper; Sydney Webb; Rohit Dhall; Anhar Hassan; Delana Weis; Steven DeMello; Sara S Riggare; Paul Wicks; Joseph Smith; H Tait Keenan; Ryan Korn; Heidi Schwarz; Saloni Sharma; E Anna Stevenson; William Zhu Journal: Telemed J E Health Date: 2016-02-17 Impact factor: 3.536
Authors: Rachel L Randell; Lindsay Singler; Anthony Cunningham; Laura E Schanberg; Michael Cohen-Wolkowiez; Christoph P Hornik; Stephen J Balevic Journal: Lupus Sci Med Date: 2021-05
Authors: Meredith A Achey; Christopher A Beck; Denise B Beran; Cynthia M Boyd; Peter N Schmidt; Allison W Willis; Sara S Riggare; Richard B Simone; Kevin M Biglan; E Ray Dorsey Journal: Trials Date: 2014-11-27 Impact factor: 2.279